Taking stock of the drug industry, from the lab to the medicine chestFebruary 1, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Adobe STAT+ | 6 things to know about Apellis' eye drug ahead of FDA decision Apellis Pharmaceuticals, the drug's maker, has expressed public confidence in the data supporting approval. Investors are more divided. By Adam Feuerstein STAT+ | 'Ill-gotten gains': FTC commissioner says GoodRx's $1.5 million fine for health data leaks should have been higher The FTC will fine GoodRx $1.5 million for leaking sensitive health data. To one of the commissioners, though, that's chump change. By Brittany Trang STAT+ | Medicare Advantage insurers will score $2 billion gift thanks to limited audits A new rule will give a free pass to Medicare Advantage plans for any erroneous codes they submitted between 2011 and 2017. By Bob Herman and Tara Bannow Alex Hogan/STAT STAT+ | New antidepressant study provides hints to Verily's future A small Phase 2 trial of a new antidepressant may hold clues to the direction of Verily, the high-profile Alphabet health tech spinout. By Matthew Herper and Casey Ross STAT+ | KKR veteran sets records with $3.9 billion health care fund Patient Square Capital closed on $3.9 billion for its fund, the largest inaugural fund for a new U.S.-based private equity firm. By Allison DeAngelis More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments